No profile data available.
CytomX Therapeutics, Inc. (CTMX) is a healthcare company in the additional cancer treatment drugs industry, based in South San Francisco, United States, with about 69 full-time employees.
It reported revenue of $76.20 million for fiscal year 2025, down 44.8% from fiscal year 2024, and net income of -$17.37 million. Its market capitalization was $560.00 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
CytomX Therapeutics reported $76.20 million in revenue for fiscal year 2025, down 44.8% from $138.10 million in fiscal year 2024.
$560.00 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Verastem, Inc. (VSTM), Nuvectis Pharma, Inc. (NVCT), Aura Biosciences, Inc. (AURA), Crescent Biopharma, Inc. (CBIO).